Sign In

Avrum Spira

Global Head, Lung Cancer Initiative at Johnson & Johnson

Professional Background

Avrum “Avi” Spira, MD, MSC, has emerged as a leading figure in the realm of lung cancer research and treatment. His role as the Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson propels his commitment to developing groundbreaking strategies that aim to prevent, intercept, and cure lung cancer. With over two decades of experience in practicing medicine, Dr. Spira oversees an innovative team dedicated to advancing technologies that facilitate earlier detection and treatment of lung cancer, moving the boundaries of what is possible in cancer care.

In addition to his responsibilities at Johnson & Johnson, Dr. Spira continues to engage actively in clinical practice as an attending physician in the Medical Intensive Care Unit at Boston University-Boston Medical Center (BMC). His dual role as a practitioner in a demanding medical environment and as a leader in cancer research reflects his dedication to both the clinical and scientific aspects of medicine. Further showcasing his commitment to education and scientific advancement, Dr. Spira holds the title of Professor of Medicine, Bioinformatics, and Pathology at Boston University, where he disseminates knowledge and mentorship to aspiring healthcare professionals and researchers. Additionally, he is recognized as the Alexander Graham Bell Professor in Health Care Entrepreneurship at Boston University, which underscores his dedication to fostering innovative solutions in health care.

Dr. Spira's distinguished career includes impactful leadership roles. Before joining Johnson & Johnson, he was the Director of the Boston University-BMC Cancer Center and the founding Chief of the Division of Computational Biomedicine at Boston University. His forward-thinking initiatives and leadership roles have always aimed at bridging the gap between research and clinical practices, ensuring that scientific advancements translate effectively into beneficial patient outcomes.

Education and Achievements

Dr. Spira’s academic journey laid a solid foundation for his illustrious career. He pursued his Doctor of Medicine (MD) degree at McGill University, where he developed a robust understanding of medical practices and patient care. Following this, he completed his residency in Internal Medicine at the esteemed University of Toronto, honing his clinical skills and deepening his understanding of complex medical conditions.

In pursuit of further specialization, Dr. Spira studied Bioinformatics at Boston University, earning a Master of Science (MS) degree. This field has been crucial in shaping his research focus, particularly in understanding the genomic alterations associated with smoking-related lung diseases. Dr. Spira’s educational credentials reflect a balanced combination of medical expertise, research acumen, and innovative thinking.

Dr. Spira’s exceptional contributions to the field of lung cancer research have led to significant advancements. His efforts culminated in the development of a molecular test for the early detection of lung cancer, known as PerceptaTM, which has been successfully translated into clinical practice. This test showcases the potential of genomic research to revolutionize cancer detection and demonstrates Dr. Spira’s impact on improving patient outcomes.

In addition to Percepta, Dr. Spira is spearheading the development of a novel therapeutic for chronic obstructive pulmonary disease (COPD), which is currently in preclinical stages. His innovative approach to preemptive care and intervention in lung diseases has positioned him as a pioneer in the field.

Dr. Spira's research excellence is further highlighted by his role as a Principal Investigator on significant grants from various institutes, including the National Institutes of Health (NIH) and the Department of Defense. His leadership in the Stand-Up-2-Cancer Lung Cancer Interception Dream Team is a testament to his dedication to collaborative efforts that aim to intercept cancer at its earliest stages.

With over 140 peer-reviewed publications to his name, Dr. Spira is a respected voice in the scientific community. His election as a member of the American Society for Clinical Investigation (ASCI) in 2010 demonstrates his peers’ recognition of his accomplishments and contributions to clinical research. In addition, he has been a member of the Association of American Physicians (AAP) since 2017, which further cements his status as a leader in the medical community.

Achievements

Throughout his career, Avrum Spira has amassed a plethora of achievements that underscore his expertise and commitment to the medical field. His pioneering work in lung cancer prevention and treatment exemplifies his role as a trailblazer in the medical community. The innovative developments under his leadership, particularly the Percepta molecular test for early detection of lung cancer, are monumental strides that highlight his capacity to integrate research f

Highlights

Aug 1 · linkedin

Each year, #WorldLungCancerDay marks an opportunity for us to reflect and celebrate the advancements made across the scientific community that are moving us closer to better prevention, interception and treatment of the disease. But despite these efforts, unmet needs remain staggering, and more than half of lung cancer cases metastasize by the time a diagnosis is made.

Statistics like these are the driving force behind our work at Johnson & Johnson and The Janssen Pharmaceutical Companies of Johnson & Johnson, where we are working to advance research and development to bring forward innovative diagnostic and treatment options, and ultimately, improve patient outcomes.

Learn more: bit.ly/3qa58I5

#MyCompany

Jul 10 · linkedin

We are very excited about our new license agreement with Nanobiotix (https://bit.ly/3PQX0GW) for the co-development and commercialization of a potential first-in-class intratumoral therapy that augments the tumor-killing effects of radiation, promising better patient outcomes. The agreement reflects our strategy to develop powerful locally delivered cancer treatments that transform the trajectory of lung and adjacent cancers.   This agreement also reflects the launch of our new Interventional Oncology R&D unit, leveraging the unique convergence of Pharmaceutical and MedTech expertise at Johnson & Johnson. The Interventional Oncology team will be built on the foundation established by the Lung Cancer Initiative and focus on delivering novel drug and energy therapies directly into lung and other tumors via minimally invasive procedures to improve patients’ lives.   #Oncology #Cancer #MyCompany

Related Questions

How did Avrum Spira develop his leadership skills in lung cancer research at Johnson & Johnson?
What innovative approaches has Avrum Spira implemented to improve early detection of lung cancer?
How has Avrum Spira’s educational background influenced his research on smoking-related diseases?
What are the future directions of Avrum Spira’s research in lung cancer interception?
How does Avrum Spira balance his roles in clinical practice and leadership in medical research?
Avrum Spira
Add to my network

Location

Greater Boston